Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
Celltrion’s influenza antibody patented in Australia, Japan
By 최희석Published : Aug. 29, 2016 - 16:25
[THE INVESTOR] South Korean biotechnology firm Celltrion announced on Aug. 29 that it has obtained patents regarding CT-P23 antibody specific to influenza A virus in Australia and Japan.
According to the company, the monoclonal antibody demonstrates neutralizing activity against H1, H3, H5, H7 and H9 strains of the virus.
In addition to Australia and Japan, the antibody has been patented in six other countries and regions including China and the US, the company said. According to Celltrion, the patents are valid in 56 nations.
The company said that CT-P23 is highly effective in diagnosing and treating conditions related to the influenza A virus, and that it is currently developing influenza treatment by combining CT-P27.
By Choi He-suk (cheesuk@heraldcorp.com)
